Raising growth-stage capital in medtech.
Growth rounds fund device leaders through broad launch, new indications and new markets. Investors read you like a listed device company.
Medtech
Medtech investors fund a device through three gates: a regulatory pathway, clinical evidence and a way to get paid. Your FDA route sets how much capital you need and how long it takes.
What growth investors expect in medtech
Growth investors compare you with listed device companies. Be ready for that lens.
Predictable revenue
- Several years of growing procedure volume
- Revenue spread across many hospitals and regions
- Recurring sales from disposables or service
Label and market expansion
- New indications filed or cleared
- Approval in markets outside the US, if planned
- A next-generation device in development
Exit readiness
- Audited accounts and strong governance
- A clean record with regulators and auditors
- A credible route to listing or sale
How the round comes together
Growth medtech rounds come from growth funds, crossover investors and health care private equity.
- 1 · A growth fund leads
- 2 · Insiders and families
- 3 · Strategics
Multi-stage VCs
Often leads
Growth and crossover funds lead most late device rounds.
Corporate VCs
Sometimes
Device makers invest ahead of a possible acquisition.
Family offices
Often follows
Large families write sizeable late-stage checks.
Angels
Now and then
Individuals rarely take part, except through secondary sales.
Structure decides the outcome
Growth rounds can include structured terms, venture debt or revenue-based financing. Each changes who is paid first in a sale. A clean, simple round is often worth a lower headline valuation.
The slides investors read first
Scale
Procedures, accounts and revenue today.
Expansion
New indications, markets and devices.
Margins
Unit cost and recurring revenue mix.
Quality
Regulatory and audit record at scale.
Exit
Timeline and the route you expect.
Questions founders ask
Do most medtech companies exit by acquisition?
Many do, because large device makers buy proven products to add to their sales channels. Some list publicly when growth and scale support it.
Is venture debt common in late-stage medtech?
It is often used beside equity to fund inventory and launch costs. Read the covenants closely, since missing one can give the lender control.
Sources
Sources: FDA guidance on device classification, 510(k), De Novo and PMA pathways; CMS coverage and coding resources; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.